Financials data is unavailable for this security.
View more
Year on year Amgen Inc had little change in net income (from 6.55bn to 6.72bn) despite revenues that grew 7.09% from 26.32bn to 28.19bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 24.34% to 29.85%.
| Gross margin | 60.48% |
|---|---|
| Net profit margin | 13.00% |
| Operating margin | 19.91% |
| Return on assets | 4.66% |
|---|---|
| Return on equity | 55.72% |
| Return on investment | 5.87% |
More ▼
Cash flow in USDView more
In 2023, Amgen Inc increased its cash reserves by 43.45%, or 3.32bn. Cash Flow from Financing totalled 21.05bn or 74.66% of revenues. In addition the company generated 8.47bn in cash from operations while cash used for investing totalled 26.20bn.
| Cash flow per share | 18.18 |
|---|---|
| Price/Cash flow per share | 16.15 |
| Book value per share | 14.00 |
|---|---|
| Tangible book value per share | -74.51 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.32 |
|---|---|
| Quick ratio | 0.9553 |
| Total debt/total equity | 8.02 |
|---|---|
| Total debt/total capital | 0.8892 |
More ▼
Growth rates in USD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 9.79% and 3.09%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.85% |
|---|---|
| Div growth rate (5 year) | 10.04% |
| Payout ratio (TTM) | 141.80% |
| EPS growth(5 years) | -0.2187 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -44.45 |
More ▼
